Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Company Deals

Digital Precision Medicine Raises Hundreds of Millions in Series B Financing for Molecular Imaging Innovation

Fineline Cube Jul 19, 2022

China-based Digital Precision Medicine (DPM), a molecular imaging and fluorescence endoscopy manufacturer, has reportedly raised...

Company Drug

Sihuan Pharma’s Fourth-Gen Insulin Degludec NDA Accepted by NMPA for Review

Fineline Cube Jul 19, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that its New Drug Application (NDA)...

Company Drug

Sihuan Pharma’s Anaprazole Enters Phase II Study for Reflux Esophagitis

Fineline Cube Jul 19, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that its subsidiary Xuanzhu Biopharmaceutical Co.,...

Company R&D

Takeda Opens R&D Asia-Pacific Headquarters in Shanghai to Boost Drug Development

Fineline Cube Jul 19, 2022

Japan’s Takeda Pharmaceutical Co., Ltd has inaugurated its R&D Asia-Pacific headquarters in Pudong, Shanghai. The...

Company Deals

Tongling Bionic Raises Hundreds of Millions in Series B Financing for Cardiopulmonary Equipment Development

Fineline Cube Jul 19, 2022

Anhui Tongling Bionic Technology Co., Ltd, a Chinese developer of cardiopulmonary circulatory assist equipment, has...

Company Drug

Sesen Bio Terminates Vicineum Development After FDA Talks, Citing Phase III Costs

Fineline Cube Jul 19, 2022

Sesen Bio Inc. (NASDAQ: SESN) announced the termination of clinical development for Vicineum (VB4-845), its...

Company Medical Device

Huadong Medicine’s GFR Monitoring System Accepted by NMPA for Review

Fineline Cube Jul 19, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a glomerular...

Company Drug

Roche’s Chugai Launches Edirol in China for Postmenopausal Osteoporosis

Fineline Cube Jul 19, 2022

Swiss pharma giant Roche’s subsidiary Chugai Pharmaceutical Co Ltd has officially launched Edirol (eldecalcitol), an...

Company Drug

Humanwell Healthcare’s RFUS-144 Wins NMPA Approval for Pruritus Clinical Study

Fineline Cube Jul 19, 2022

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Category 1 drug RFUS-144...

Company Deals

Brii Biosciences Partners with Huarun Medicine to Commercialize COVID-19 Antibody Cocktail in China

Fineline Cube Jul 19, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced a partnership with Huarun Medicine Business Group International...

Company Drug

Hengrui Medicine Launches Revelutamide for Metastatic Prostate Cancer in China

Fineline Cube Jul 19, 2022

Hengrui Medicine has launched revelutamide (SHR3680; trade name: Erion), China’s homegrown innovative androgen receptor (AR)...

Company Deals

Chongqing Lummy Pharma Cancels YZY Biopharma Y400 Partnership, Secures Compensation

Fineline Cube Jul 19, 2022

China’s Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) announced the termination of its strategic partnership...

Drug

HutchMed Initiates Phase I Study of CD47 Monoclonal Antibody HMPL-A83 in China

Fineline Cube Jul 19, 2022

China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase I clinical study...

Company Deals

Grand Pharma Acquires Stake in Xeltis and Licenses aXess for Hemodialysis in Greater China

Fineline Cube Jul 19, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in...

Company Deals

Fermion Secures Series B Financing to Advance AI-Driven Drug Development

Fineline Cube Jul 18, 2022

Guangzhou-based AI biotech Fermion has raised over RMB100 million ($14.8 million) in a Series B...

Company Deals

Biotree Raises $14.8M in Series A Financing to Expand Multi-Omics Platform

Fineline Cube Jul 18, 2022

Shanghai-based multi-omics specialist Biotree has raised nearly RMB100 million ($14.8 million) in a Series A...

Company Drug

Kexing Pharmaceutical’s SHEN26 COVID-19 Drug Receives NMPA Approval for Clinical Trials

Fineline Cube Jul 18, 2022

China-based Kexing Pharmaceutical (SHA: 688136) announced that its oral small-molecule COVID-19 drug SHEN26, co-developed with...

Company Deals Digital

WeDoctor Partners with Jinan Innovation Zone to Launch Dual Healthcare Platform

Fineline Cube Jul 18, 2022

China-based WeDoctor Holdings Ltd, a Tencent-backed online medical service platform, has partnered with Jinan Innovation...

Company Drug

ImmuneOnco’s IMM2902 Receives FDA Fast-Track Designation for CD47/HER2 Targeting

Fineline Cube Jul 18, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that the U.S. Food and Drug Administration (FDA) has...

Policy / Regulatory

VBP Round 7 Drug Procurement Contract Awards Top Winners Revealed

Fineline Cube Jul 18, 2022

China’s 7th national Volume-Based Procurement (VBP) round concluded with winning bids for 60 drug products...

Posts pagination

1 … 595 596 597 … 613

Recent updates

  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
  • Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
  • PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.